Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics
.

Adedoyin A, Cho CR, Fox-Bosetti S, Macha S, Zhao T, Liu F, Panebianco D, O'Reilly TE, McCrea J, Stoch SA, Iwamoto M.

Int J Clin Pharmacol Ther. 2019 Jun 24. doi: 10.5414/CP203483. [Epub ahead of print]

PMID:
31232280
2.

First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers.

Fox JC, Hellawell JL, Rao S, O'Reilly T, Lumpkin R, Jernelius J, Gretler D, Sinha U.

Clin Pharmacol Drug Dev. 2019 Jun 6. doi: 10.1002/cpdd.700. [Epub ahead of print]

PMID:
31172685
3.

Powerful turbidity currents driven by dense basal layers.

Paull CK, Talling PJ, Maier KL, Parsons D, Xu J, Caress DW, Gwiazda R, Lundsten EM, Anderson K, Barry JP, Chaffey M, O'Reilly T, Rosenberger KJ, Gales JA, Kieft B, McGann M, Simmons SM, McCann M, Sumner EJ, Clare MA, Cartigny MJ.

Nat Commun. 2018 Oct 5;9(1):4114. doi: 10.1038/s41467-018-06254-6.

4.

Media reporting of suicide and adherence to media guidelines.

McTernan N, Spillane A, Cully G, Cusack E, O'Reilly T, Arensman E.

Int J Soc Psychiatry. 2018 Sep;64(6):536-544. doi: 10.1177/0020764018784624. Epub 2018 Jul 4.

PMID:
29972096
5.

Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models.

Becquet M, Laborde L, Texier C, Sterker D, Gschwind HP, Pfaar U, Wartmann M, O'Reilly TM, McSheehy PM.

Anticancer Drugs. 2018 Aug;29(7):691-701. doi: 10.1097/CAD.0000000000000639.

PMID:
29734209
6.

Modular transmit/receive arrays using very-high permittivity dielectric resonator antennas.

O'Reilly TPA, Ruytenberg T, Webb AG.

Magn Reson Med. 2018 Mar;79(3):1781-1788. doi: 10.1002/mrm.26784. Epub 2017 Jun 20.

7.

No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.

Marshall WL, Feng HP, Caro L, Talaty J, Guo Z, Huang X, Panebianco D, Ma J, Mangin E, O'Reilly TE, Butterton JR, Yeh WW.

Eur J Clin Pharmacol. 2017 May;73(5):593-600. doi: 10.1007/s00228-017-2216-4. Epub 2017 Feb 24.

PMID:
28233047
8.

Practical improvements in the design of high permittivity pads for dielectric shimming in neuroimaging at 7T.

O'Reilly TPA, Webb AG, Brink WM.

J Magn Reson. 2016 Sep;270:108-114. doi: 10.1016/j.jmr.2016.07.003. Epub 2016 Jul 9.

PMID:
27434779
9.

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval.

Mendell J, Matsushima N, O'Reilly TE, Lee J.

J Clin Pharmacol. 2016 Apr;56(4):484-91. doi: 10.1002/jcph.610. Epub 2015 Nov 9.

10.

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.

Nguyen L, Holland J, Miles D, Engel C, Benrimoh N, O'Reilly T, Lacy S.

J Clin Pharmacol. 2015 Sep;55(9):1012-23. doi: 10.1002/jcph.510. Epub 2015 Jun 2.

PMID:
25854986
11.

Combined treatment strategies for microtubule stabilizing agent-resistant tumors.

Broggini-Tenzer A, Sharma A, Nytko KJ, Bender S, Vuong V, Orlowski K, Hug D, O'Reilly T, Pruschy M.

J Natl Cancer Inst. 2015 Feb 17;107(4). pii: dju504. doi: 10.1093/jnci/dju504. Print 2015 Apr.

PMID:
25694444
12.

Plasmonic enhancement of dye sensitized solar cells via a tailored size-distribution of chemically functionalized gold nanoparticles.

Andrei C, Lestini E, Crosbie S, de Frein C, O'Reilly T, Zerulla D.

PLoS One. 2014 Oct 29;9(10):e109836. doi: 10.1371/journal.pone.0109836. eCollection 2014.

13.

Chemistry of silica scale mitigation for RO desalination with particular reference to remote operations.

Milne NA, O'Reilly T, Sanciolo P, Ostarcevic E, Beighton M, Taylor K, Mullett M, Tarquin AJ, Gray SR.

Water Res. 2014 Nov 15;65:107-33. doi: 10.1016/j.watres.2014.07.010. Epub 2014 Jul 12. Review.

PMID:
25105586
14.

Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone.

Lin WH, Feng HP, Shadle CR, O'Reilly T, Wagner JA, Butterton JR.

Eur J Clin Pharmacol. 2014 Sep;70(9):1107-13. doi: 10.1007/s00228-014-1711-0. Epub 2014 Jul 5.

PMID:
24992979
15.

Validation of a postfixation tissue storage and transport medium to preserve histopathology and molecular pathology analyses (total and phosphoactivated proteins, and FISH).

Stumm MM, Walker MR, Stork C, Hanoteau N, Wagner U, O'Reilly TM.

Am J Clin Pathol. 2012 Mar;137(3):429-36. doi: 10.1309/AJCPDZ4FAQ9BUEXC.

PMID:
22338055
16.

Steve Jobs (1955-2011).

O'Reilly T.

Nature. 2011 Nov 2;479(7371):42. doi: 10.1038/479042a. No abstract available.

PMID:
22051667
17.

Research and innovation in the development of everolimus for oncology.

Lebwohl D, Thomas G, Lane HA, O'Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi JF, Stewart J, Motzer RJ.

Expert Opin Drug Discov. 2011 Mar;6(3):323-38. doi: 10.1517/17460441.2011.558079. Epub 2011 Feb 17.

PMID:
22647206
18.

Th17 cells, not IL-17+ γδ T cells, drive arthritic bone destruction in mice and humans.

Pöllinger B, Junt T, Metzler B, Walker UA, Tyndall A, Allard C, Bay S, Keller R, Raulf F, Di Padova F, O'Reilly T, Horwood NJ, Patel DD, Littlewood-Evans A.

J Immunol. 2011 Feb 15;186(4):2602-12. doi: 10.4049/jimmunol.1003370. Epub 2011 Jan 7.

19.

Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis.

Ito M, Barys L, O'Reilly T, Young S, Gorbatcheva B, Monahan J, Zumstein-Mecker S, Choong PF, Dickinson I, Crowe P, Hemmings C, Desai J, Thomas DM, Lisztwan J.

Clin Cancer Res. 2011 Feb 1;17(3):416-26. doi: 10.1158/1078-0432.CCR-10-2050. Epub 2010 Dec 15.

20.

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.

O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA.

Anticancer Drugs. 2011 Jan;22(1):58-78. doi: 10.1097/CAD.0b013e3283400a20.

PMID:
20890178
21.

Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET.

Honer M, Ebenhan T, Allegrini PR, Ametamey SM, Becquet M, Cannet C, Lane HA, O'Reilly TM, Schubiger PA, Sticker-Jantscheff M, Stumm M, McSheehy PM.

Transl Oncol. 2010 Aug 1;3(4):264-75.

22.

Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.

O'Reilly T, Lane HA, Wood JM, Schnell C, Littlewood-Evans A, Brueggen J, McSheehy PM.

Cancer Chemother Pharmacol. 2011 Jan;67(1):193-200. doi: 10.1007/s00280-010-1307-z. Epub 2010 May 30.

PMID:
20512579
23.

A spatially resolved study on the Sn diffusion during the sintering process in the active layer of dye sensitised solar cells.

Andrei C, O'Reilly T, Zerulla D.

Phys Chem Chem Phys. 2010 Jul 14;12(26):7241-5. doi: 10.1039/c000072h. Epub 2010 May 21.

PMID:
20495722
25.

Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.

O'Reilly T, McSheehy PM, Kawai R, Kretz O, McMahon L, Brueggen J, Bruelisauer A, Gschwind HP, Allegrini PR, Lane HA.

Cancer Chemother Pharmacol. 2010 Mar;65(4):625-39. doi: 10.1007/s00280-009-1068-8. Epub 2009 Sep 27.

PMID:
19784839
26.

Effects of ankle-foot orthoses for children with hemiplegia on weight-bearing and functional ability.

O'Reilly T, Hunt A, Thomas B, Harris L, Burns J.

Pediatr Phys Ther. 2009 Fall;21(3):225-34. doi: 10.1097/PEP.0b013e3181b126fb.

PMID:
19680063
27.

Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.

Nick H, Allegrini PR, Fozard L, Junker U, Rojkjaer L, Salie R, Niederkofler V, O'Reilly T.

Exp Biol Med (Maywood). 2009 May;234(5):492-503. doi: 10.3181/0811-RM-337. Epub 2009 Feb 20.

PMID:
19234060
28.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.

29.

Dispensary level pilot implementation of rapid diagnostic tests: an evaluation of RDT acceptance and usage by providers and patients--Tanzania, 2005.

Williams HA, Causer L, Metta E, Malila A, O'Reilly T, Abdulla S, Kachur SP, Bloland PB.

Malar J. 2008 Nov 19;7:239. doi: 10.1186/1475-2875-7-239.

30.

Where's the difficulty in standardized reading tests: the passage or the question?

Ozuru Y, Rowe M, O'Reilly T, McNamara DS.

Behav Res Methods. 2008 Nov;40(4):1001-15. doi: 10.3758/BRM.40.4.1001.

PMID:
19001391
31.

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.

Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, Maira SM.

Cancer Res. 2008 Aug 15;68(16):6598-607. doi: 10.1158/0008-5472.CAN-08-1044.

32.

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA.

J Clin Oncol. 2008 Apr 1;26(10):1596-602. doi: 10.1200/JCO.2007.14.1127. Epub 2008 Mar 10.

PMID:
18332467
33.

Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.

O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1045-54. doi: 10.1007/s00280-008-0695-9. Epub 2008 Feb 27.

PMID:
18301895
34.

Systemic inflammation alters the inflammatory response in experimental lipopolysaccharide-induced meningitis.

O'Reilly T, Ostergaard C, Vaxelaire J, Zak O.

Clin Exp Immunol. 2007 Jan;147(1):112-9.

35.

Influence of the blood bacterial load on the meningeal inflammatory response in Streptococcus pneumoniae meningitis.

Østergaard C, O'Reilly T, Brandt C, Frimodt-Møller N, Lundgren JD.

BMC Infect Dis. 2006 Apr 27;6:78.

36.

Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish.

Bayliss PE, Bellavance KL, Whitehead GG, Abrams JM, Aegerter S, Robbins HS, Cowan DB, Keating MT, O'Reilly T, Wood JM, Roberts TM, Chan J.

Nat Chem Biol. 2006 May;2(5):265-73. Epub 2006 Mar 26.

37.

Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.

LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T, Wood J.

Cancer Res. 2006 Jan 1;66(1):221-31.

38.

Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure.

Ferretti S, Allegrini PR, O'Reilly T, Schnell C, Stumm M, Wartmann M, Wood J, McSheehy PM.

Clin Cancer Res. 2005 Nov 1;11(21):7773-84.

39.

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.

Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA.

Clin Cancer Res. 2005 Jul 15;11(14):5319-28.

40.

The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.

Sini P, Wyder L, Schnell C, O'Reilly T, Littlewood A, Brandt R, Hynes NE, Wood J.

Clin Cancer Res. 2005 Jun 15;11(12):4521-32.

41.

Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.

O'Reilly T, McSheehy PM, Wenger F, Hattenberger M, Muller M, Vaxelaire J, Altmann KH, Wartmann M.

Prostate. 2005 Nov 1;65(3):231-40.

PMID:
15948135
42.

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G.

Cell. 2005 Mar 25;120(6):747-59.

43.

Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.

O'Reilly T, Wartmann M, Maira SM, Hattenberger M, Vaxelaire J, Muller M, Ferretti S, Buchdunger E, Altmann KH, McSheehy PMJ.

Cancer Chemother Pharmacol. 2005 Apr;55(4):307-317. doi: 10.1007/s00280-004-0913-z. Epub 2004 Oct 26.

PMID:
15723258
44.

Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.

Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O'Reilly T, Lane H, Susa M.

Bone. 2004 Nov;35(5):1144-56.

PMID:
15542040
45.

4. The natural products epothilones A and B as lead structures for anticancer drug discovery: chemistry, biology, and SAR studies.

Altmann KH, Flörsheimer A, O'Reilly T, Wartmann M.

Prog Med Chem. 2004;42:171-205. Review. No abstract available.

PMID:
15003721
46.

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G, Lane HA.

Cancer Res. 2004 Jan 1;64(1):252-61.

48.

A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs.

Spooner RA, Friedlos F, Maycroft K, Stribbling SM, Roussel J, Brueggen J, Stolz B, O'Reilly T, Wood J, Matter A, Marais R, Springer CJ.

Br J Cancer. 2003 May 19;88(10):1622-30.

49.

Functional-morphologic MR imaging with ultrasmall superparamagnetic particles of iron oxide in acute and chronic soft-tissue infection: study in rats.

Kaim AH, Jundt G, Wischer T, O'Reilly T, Frohlich J, von Schulthess GK, Allegrini PR.

Radiology. 2003 Apr;227(1):169-74. Epub 2003 Feb 28.

PMID:
12615996
50.

Pharmacology of imatinib (STI571).

Buchdunger E, O'Reilly T, Wood J.

Eur J Cancer. 2002 Sep;38 Suppl 5:S28-36. Review.

PMID:
12528770

Supplemental Content

Loading ...
Support Center